-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2382 Efficacy and Safety Profile of Proteasome Inhibitor Based Drug Regimens for Treatment of Newly Diagnosed AL Amyloidosis: A Systematic Review

Program: Oral and Poster Abstracts
Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster II
Hematology Disease Topics & Pathways:
Diseases, Non-Biological, neurotoxicity, Therapies, Adverse Events, chemotherapy, Myeloid Malignancies
Sunday, December 6, 2020, 7:00 AM-3:30 PM

Saad Javed, MD1*, Tariq Iqtidar Sadiq Syed, MD2*, Hejab Fatima, MBBS3*, Syed Hashim Ali Inam, MBBS4*, Tayyab Rehan, MBBS5*, Syed Maaz Abdullah, MBBS6*, Mohammed Musa Najmuddin, MBBS3*, Mobeen Zaka Haider, MD, MBBS7*, Karun Neupane, MBBS, MD8*, Muhammad Khawar Sana, MD9*, Abdul Jabbar Dar, MD10*, Ali Jaan, MD11*, Muhammad Ali Mirza, MD12* and Faiz Anwer, MD13

1Department of Internal Medicine, Allama Iqbal Medical College, Lahore, Pakistan
2Internal Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, bronx, NY
3Allama Iqbal Medical College, Lahore, Pakistan
4Internal Medicine, Army Medical College, Rawalpindi, Pakistan
5Nishtar Medical University, Multan, Pakistan
6King Edward Medical University, Lahore, Punjab, Pakistan
7King Edward Medical University, Sartell, MN
8Manipal College of Medical Sciences, Pokhara, Nepal
9Department of Internal Medicine, King Edward Medical University, Lahore, AL, Pakistan
10Shaikh Zayed Medical College, Lahore, Pakistan
11King Edward Medical University, Lahore, Pakistan
12Department of Medicine, Frontier Medical And Dental College, Abbottabad, ON, Pakistan
13Department of Hematology & Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Moreland Hills, OH


Light chain amyloidosis (AL) is a plasma cell disorder associated with detrimental manifestations in multiple organ systems of the body. It is estimated that approximately 1275-3200 new cases occur in the United States annually. Proteasome inhibitors (PI), such as bortezomib, carfilzomib, and ixazomib used for multiple myeloma treatment are also used for the treatment of AL amyloidosis. Our aim in this review is to evaluate the efficacy and safety profile of PI-based regimens for the treatment of newly diagnosed AL Amyloidosis (ND-AL).


We conducted a systematic review (following PRISMA guidelines) by completing a comprehensive literature search on PubMed, Cochrane, ClinicalTrials.gov, and Embase on June 23rd, 2020. We were able to identify 901 articles, 325 articles from PubMed, 50 from Cochrane, 23 from Clinical Trials.org, and 253 from Embase. After the screening, we selected 11 published studies (n=436) including 5 phase lll trials, 2 phase I/II trials.


  1. Cyclophosphamide, Bortezomib, Dexamethasone (CyBorD) with or without Daratumumab (Dara):

In a Phase lll trial (ANDEROMADA study), Palldini et al. (2020) studied the efficacy of Dara+ CyBorD vs CyBorD in ND-AL pts (n=28). The addition of Dara to CyBorD showed an improved overall hematological response (ORR) in 96% with complete response (CR) in 54% pts at a median follow up of 17.6 months (Table 1).

In a retrospective study by Lim et al. (2017), CyBorD was given to ND-AL pts (n=39) which showed an ORR in 63% with very good partial response (VGPR) in 50% pts.

In a retrospective study by Diaz-Pallares et al. (2020), CyBord was given to ND-AL pts (n=34) which showed an ORR in 91% with CR, VGPR, and partial response (PR) in 26%, 26%, and 38% pts, respectively. Progression-free survival (PFS) and overall survival (OS) were reported at 26.7 months and 22 months (P=0.06) respectively (Table 1).

  1. Bortezomib, Melphalan, Dexamethasone (BMD):

In a phase III trial (EMN-03 study), Kastritis et al. (2020) studied the efficacy of BMD vs MD in ND-AL pts (n=109). Addition of B to MD showed an improved ORR: 81% vs 56% (p=0.001) with CR/VGPR in 53% vs 28% pts. No significant difference in survival outcome was observed.

In a phase III trial, Kastritis et al. (2015) studied the efficacy of BMD vs MD in ND-AL pts (n=69). Addition of B to MD showed an improved ORR: 75% vs 53% (p=0.075) with CR/VGPR in 56% vs 42% pts (p=0.277). OS and PFS were also improved in BMD group as compared to control group: 83% vs 72% (p= 0.295) and 61% vs 49% (p=0.079) at 2 years, respectively (Table 1).

  1. Bortezomib, Melphalan, Prednisolone (BMP):

In a retrospective study by Lee et al. (2014), BMP was given to ND-AL pts (n=19) which showed an ORR in 84% pts with CR, VGPR and PR in 37%, 21% and 26% pts, respectively (Table 1).

  1. Induction with B based regimens for ASCT:

In a Phase lll trial (HOVON 104), Minnema et al. (2019), studied the efficacy of BD induction prior to HDM/ASCT in pts (n=35) with ND-AL. At 6 months, BD induction prior to HDM/ASCT vs No BD Induction prior to HDM/ASCT showed an ORR: 80% vs 80% with an improved CR: 43% vs 5% and VGPR: 54% vs 51%.

In a Phase I/II trial by Sanchorawala et al. (2015), BD induction followed by B-HDM conditioning for ASCT was done in pts (n=27) with ND-AL. ORR at 6 months post ASCT was observed in 100% pts with CR and VGPR in 63% and 37% pts, respectively (Table 1).

  1. Induction with B based regimen prior to ASCT vs Upfront ASCT:

In a retrospective analysis by Scharman et al. (2017), 53 pts who received ASCT were categorized into 3 groups i.e. Upfront ASCT, induction with B based regimen and induction with other regimens. ND-AL Patients (n=34/53) receiving B based induction vs no induction showed an improved ORR: 94% vs 69% (p=0.04). OS also improved in B based induction as compared to no induction group: 87% vs 77% (p=0.22) at 3 years. PFS at 3 years was 61% vs 69%, respectively (Table 1).


PI-based regimens have shown favorable outcomes in the treatment of ND-AL and are effective therapeutic options. The most promising results are observed with CyBorD+Dara. The adverse events associated with PI-based therapy are peripheral neuropathy, anemia, thrombocytopenia, and infections. Further prospective clinical trials are warranted for a broader understanding of the safety and efficacy profile of PI-based regimens and correlation with individual pts characteristics.

Table Caption:

Table 1: Comparative efficacy and safety of proteasome-inhibitor based drug regimens in ND-AL

Disclosures: Anwer: Incyte, Seattle Genetics, Acetylon Pharmaceuticals, AbbVie Pharma, Astellas Pharma, Celegene, Millennium Pharmaceuticals.: Honoraria, Research Funding, Speakers Bureau.

*signifies non-member of ASH